Rectum motion and morbidity prediction: Improving correlation between late morbidity and DVH parameters through use of rectum planning organ at risk volumes

Acta Oncologica

Volumn 49, Issue 7, 2010, Pages 1061-1068

  Thor, Maria ^a,b   Væth, Michael ^b   Karlsdottir, Ása ^c   Muren, Ludvig Paul ^a,b,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DOSE VOLUME HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; MORBIDITY; PLANNING ORGAN AT RISK VOLUME; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RECTUM DISEASE; RECTUM MOTILITY; RISK ASSESSMENT; SCORING SYSTEM; SEMINAL VESICLE; TREATMENT PLANNING;

AGE OF ONSET; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MODELS, STATISTICAL; MORBIDITY; MOVEMENT; ORGAN SIZE; ORGANS AT RISK; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTAL DISEASES; RECTUM; TUMOR BURDEN;

EID: 77956590175     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.505200     Document Type: Article

References (36)

1. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:3-11.
2. Sripadam R, Stratford J, Henry AM, Jackson A, Moore CJ, Price P. Rectal motion can reduce CTV coverage and increase rectal dose during prostate radiotherapy: A daily cone-beam CT study. Radiother Oncol 2009;90:312-317
3. Perez CA, Michalski JM, Purdy JA, Wasserman TH, Williams K, Lockett MA. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: Preliminary results of a nonrandomized comparison. Int J Radiat Oncol Biol Phys 2000;47:629-637
4. Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: Evidence from MRC RT01 trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010;76:747-754
5. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatraman ES, Levegrun S, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (I I): Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001;49:685-698
6. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010;76(Suppl 3):123-129
7. Fiorino C, Valdagni R, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: Pelvis. Radiother Oncol 2009;93:153-167
8. Muren LP, Ekerold R, Kvinnsland Y, Karlsd o ttir A, Dahl O. On the use of margins for geometrical uncertainties around the rectum in radiotherapy planning. Radiother Oncol 2004;70:11-19
9. Muren LP, Karlsdottir A, Kvinnsland Y, Wentzel-Larsen T, Dahl O. Testing the new ICRU 62 ' Planning Organ at Risk Volume ' concept for the rectum. Radiother Oncol 2005;75: 293-302.
10. McKenzie A, van Herk M, Mijnheer B. Margins for geometric uncertainty around organs at risk in radiotherapy. Radi-other Oncol 2002;62:299-307.
11. ICRU Report 62. Prescribing, recording and reporting photon beam radiotherapy (supplement to ICRU Report 50). International Commission on Radiation Units and Measurements, Bethesda, MD; 1999.
12. Karlsdottir A, Johanesson DC, Muren LP, Wentzel-Larsen T, Dahl O. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radi-other Oncol 2004;71:43-53.
13. Hermanek P, Hutter RVP, Sobin LH, Spiessi B, Wagner G. TNM atlas. Illustrated guide to the TNM/pTNM classification of malignant tumours. Berlin and Heidelberg: Springer-Verlag; 1997.
14. Mellinger GT, Gleason D, Bailar J. The histology and prognosis of prostatic cancer. J Urol 1967;97:331-337
15. ICRU Report 50. Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements. Bethesda, MD; 1993.
16. Karlsd o ttir A, Muren LP, Wenzel-Larsen T, Dahl O. Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity. Int J Radiat Oncol Biol Phys 2008;70:1478-1486
17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;5:1341-1346
18. Peeters ST, Lebesque JV, Heemsbergen WD, van Putten WL, Slot A, Dielwart MF, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006;64:1151-1161
19. Wang JZ, Mayr NA, Yuh WT Behind EUD. Acta Oncol 2008; 47:971-972
20. Mohan R, Mageras GS, Baldwin B, Brewster LJ, Kutcher GJ, Leibel S, et al. Clinically relevant optimization of 3-D con-formal treatments. Med Phys 1992;19:933-944
21. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance to an analytic function. Int J Radiat Oncol Biol Phys 1991;21:123-135
22. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Lee AK, et al. Fit of a normal-tissue complication probability (NTCP) model to Grade 2 late rectal toxicity data from patients treated on protocol RTOG 94-06 [Abstract]. Int J Radiat Oncol Biol Phys 2007;69(Suppl 3):8-9.
23. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: Results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 2004;73:21-32.
24. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrün S, et al. Late rectal toxicity after conformal radiotherapy of prostate cancer I: Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000; 47:103-113
25. Gulliford SL, Partridge M, Sydes MR, Andreyev J, Dearna-ley DP. A comparison of dose-volume constraints derived using peak and longitudinal definitions of late rectal toxicity. Radiother Oncol 2010;94:241-247
26. Fokdal L, HonoréH, Høyer M, von Der Maase H. Dose-volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy. Radiother Oncol 2005;74:203-210
27. Muren LP, Wasbo E, Helle SI, Hysing LB, Karlsdo ttir A, Odland OH, et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: Planning procedures and early experiences. Int J Radiat Oncol Biol Phys 2008;71:1034-1041
28. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using " optimal " cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829-835
29. Yan D, Jaffray DA, Wong JW. A model to accumulate fractionated dose in a deforming organ. Int J Radiat Oncol Biol Phys 1999;44:665-675
30. Sanguineti G, Somani M, Eugene E, Little M, Chen G, Berilgen J, et al. Dosimetric predictors of diarrhea during radiotherapy for prostate cancer [Abstract]. Int J Radiat Oncol Biol Phys 2007;69(Suppl 3):346-347
31. Buettner F, Gulliford SL, Webb S, Sydes MR, Dearnaley DP, Partridge M. Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: An analysis of data from the MRC RT01 trial (ISRCTN 47772397). Phys Med Biol 2009;54:6535-6548
32. Grau C, Muren LP, Høyer M, Lindegaard J, Overgaard J. Image-guided adaptive radiotherapy-integration of biology and technology to improve clinical outcome. Acta Oncol 2008;47:1182-1185
33. Søndergaard J, Høyer M, Petersen JB, Wright P, Grau C, Muren LP. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol 2009;48: 238-244
34. Webb S. The contribution, history, impact and future of physics in medicine. Acta Oncol 2009;48:169-177
35. Jeraj R. Future of physics in medicine and biology. Acta Oncol 2009;48:178-184
36. Van Herk M. Will IGRT live up to its promise? Acta Oncol 2008;47:1186-1187.